参考文献/References:
[1] Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC) Developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.
[2] Calkins H,Hindricks G,Cappato R,et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation[J]. Heart Rhythm,2017,14(10):e275-e444.
[3] Gawa?ko M,Agbaedeng TA,Saljic A,et al. Gut microbiota,dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications [J]. Cardiovasc Res,2021?Sep 22:cvab292. DOI:10.1093/cvr/cvab292. Epub ahead of print.
[4] Zuo K,Li J,Li K,et al. Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation[J]. Gigascience,2019,8(6):giz058.
[5] Zuo K,Yin X,Li K,et al. Different types of atrial fibrillation share patterns of gut microbiota dysbiosis[J]. mSphere,2020,5(2):e00071-20.
[6] Zuo K,Li J,Wang P,et al. Duration of persistent atrial fibrillation is associated with alterations in human gut microbiota and metabolic phenotypes[J]. mSystems,2019,4(6):e00422-19.
[7] Li J,Zuo K,Zhang J,et al. Shifts in gut microbiome and metabolome are associated with risk of recurrent atrial fibrillation[J].?J Cell Mol Med,2020,24(22):13356-13369.
[8] Chung MK,Eckhardt LL,Chen LY,et al. Lifestyle and risk factor modification for reduction of atrial fibrillation:a scientific statement from the American Heart Association[J]. Circulation,2020,141(16):e750-e772.
[9] Witkowski M,Weeks TL,Hazen SL. Gut microbiota and cardiovascular disease[J]. Circ Res,2020,127(4):553-570.
[10] Yang S,Li X,Yang F,et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease:inflammation mechanism,clinical prognostic,and potential as a therapeutic target[J]. Front Pharmacol,2019,10:1360.
[11] Dalile B,van Oudenhove L,Vervliet B,et al. The role of short-chain fatty acids in microbiota-gut-brain communication[J]. Nat Rev Gastroenterol Hepatol,2019,16(8):461-478.
[12] Yang G,Wei J,Liu P,et al. Role of the gut microbiota in type 2 diabetes and related diseases[J]. Metabolism,2021,117:154712.
[13] Maruvada P,Leone V,Kaplan LM,et al. The human microbiome and obesity:moving beyond associations[J]. Cell Host Microbe,2017,22(5):589-599.
[14] Marques FZ,Mackay CR,Kaye DM. Beyond gut feelings:how the gut microbiota regulates blood pressure[J]. Nat Rev Cardiol,2018,15(1):20-32.
[15] Papandreou C,Bulló M,Hernández-Alonso P,et al. Choline metabolism and risk of atrial fibrillation and heart failure in the PREDIMED study[J]. Clin Chem,2021,67(1):288-297.
[16] Svingen GFT,Zuo H,Ueland PM,et al. Increased plasma trimethylamine-N-oxide is associated with incident atrial fibrillation[J]. Int J Cardiol,2018,267:100-106.
[17] Zuo K,Liu X,Wang P,et al. Metagenomic data-mining reveals enrichment of trimethylamine-N-oxide synthesis in gut microbiome in atrial fibrillation patients[J]. BMC Genomics,2020,21(1):526.
[18] Li X,Geng J,Zhao J,et al. Trimethylamine N-oxide exacerbates cardiac fibrosis via activating the NLRP3 inflammasome[J]. Front Physiol,2019,10:866.
[19] Yu L,Meng G,Huang B,et al. A potential relationship between gut microbes and atrial fibrillation:trimethylamine N-oxide,a gut microbe-derived metabolite,facilitates the progression of atrial fibrillation[J]. Int J Cardiol,2018,255:92-98.
[20] Chen YY,Sun ZW,Jiang JP,et al. α-adrenoceptor-mediated enhanced inducibility of atrial fibrillation in a canine system inflammation model[J]. Mol Med Rep,2017,15(6):3767-3774.
[21] Zhang Y,Zhang S,Li B,et al. Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome[J]. Cardiovasc Res,2021 Mar 23:cvab114. DOI:10.1093/cvr/cvab114. Epub ahead of print.
[22] Yao C,Veleva T,Scott L Jr,et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation[J]. Circulation,2018,138(20):2227-2242.
[23] Sheikh Abdul Kadir SH,Miragoli M,Abu-Hayyeh S,et al. Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes[J]. PLoS One,2010,5(3):e9689.
[24] Pu J,Yuan A,Shan P,et al. Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury[J]. Eur Heart J,2013,34(24):1834-1845.
[25] Tang WHW,Li DY,Hazen SL. Dietary metabolism,the gut microbiome,and heart failure[J]. Nat Rev Cardiol,2019,16(3):137-154.
[26] Perry RJ,Peng L,Barry NA,et al. Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome[J]. Nature,2016,534(7606):213-217.
[27] Ahmadi S,Wang S,Nagpal R,et al. A human-origin probiotic cocktail ameliorates aging-related leaky gut and inflammation via modulating the microbiota/taurine/tight junction axis[J]. JCI Insight,2020,5(9):e132055.
[28] Chen Q,Liu M,Zhang P,et al. Fucoidan and galactooligosaccharides ameliorate high-fat diet-induced dyslipidemia in rats by modulating the gut microbiota and bile acid metabolism[J]. Nutrition,2019,65:50-59.
[29] Aldana-Hernández P,Leonard KA,Zhao YY,et al. Dietary choline or trimethylamine N-oxide supplementation does not influence atherosclerosis development in Ldlr-/- and Apoe-/- male mice[J]. J Nutr,2020,150(2):249-255.
[30] Vieira-Silva S,Falony G,Belda E,et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis[J]. Nature,2020,581(7808):310-315.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(3):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(3):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]杨娟,综述,王佑华,等.肠道菌群与血管内炎症[J].心血管病学进展,2016,(3):263.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.012]
YANG Juan,WANG Youhua,YUAN Suyun.Relationship Between Gut Microbiota and Vascular Inflammation[J].Advances in Cardiovascular Diseases,2016,(3):263.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.012]
[8]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[9]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(3):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[10]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]